Key takeaways
- NAD+ is consumed as a substrate by PARP enzymes repairing DNA and by sirtuins, which is why levels fall as damage and inflammation accumulate.
- Two claims are settled: NAD+ declines with age, and oral precursors raise it.
- The third claim — that raising it improves human health outcomes — has not been demonstrated.
- Blood NAD+ is a convenient measurement, not necessarily the relevant one; the marker can move without the biology moving.
- It is a next-tier adjunct once sleep, training, nutrition and hormones are handled — not a foundation.
NAD+ occupies an awkward place in longevity medicine. The underlying biology is not controversial — the molecule is genuinely essential, it genuinely declines with age, and precursors genuinely raise it. What is contested is the step everyone cares about: whether raising a number that falls with age makes you age more slowly. The honest answer is that this has not been demonstrated in humans, and the marketing has run considerably ahead of the data. That does not make it worthless. It makes it a different category of decision from the one it is usually presented as.
What NAD+ actually is
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell you have. It is not a vitamin, a hormone or a supplement in origin — it is infrastructure. Two roles matter.
The first is electron transfer. NAD+ accepts electrons during the breakdown of fuel and carries them to the mitochondria, where they drive ATP production. In this role it is recycled rather than consumed, cycling continuously between NAD+ and NADH.
The second role is where it gets consumed, and it explains the decline. Two enzyme families use NAD+ as a substrate and destroy it in the process: PARPs, which repair DNA damage, and sirtuins, which regulate gene expression, metabolic adaptation and mitochondrial quality control. Every DNA repair event and every sirtuin reaction spends NAD+. Sirtuin biology covers the second family in detail, and the salvage pathway covers how the cell recycles what it can.
Why levels fall with age
NAD+ drops roughly 50% between age 20 and age 60 (Massudi et al., PLoS One 2012). It falls for reasons on both sides of the ledger.
- Consumption rises. Accumulated DNA damage keeps PARPs busy; chronic inflammation and metabolic stress add further demand. An ageing cell spends more NAD+ per day than a young one.
- Salvage becomes less efficient. Most NAD+ is not made from scratch but recycled from nicotinamide, and the enzymes running that loop become less effective with age.
- CD38 activity rises. This enzyme degrades NAD+ and its precursors, and it increases with age as part of the inflammatory profile of ageing tissue — meaning inflammation both consumes NAD+ and destroys it (Camacho-Pereira et al., Cell Metab 2016).
- Lifestyle contributes. Poor sleep, alcohol, sedentary behaviour and excess adiposity all push in the same direction.
That last point is the most actionable and the most often skipped: exercise, energy restriction and adequate sleep all raise NAD+ through the same salvage machinery supplements target, at no cost. The primer on NAD+ covers the basics.
Where the evidence is strong, and where it stops
The important discipline here is separating three claims that get merged together.
Claim one — NAD+ declines with age. Well supported across human tissue studies. Not in serious dispute.
Claim two — oral precursors raise NAD+. Also well supported. Nicotinamide riboside is orally bioavailable and raises blood NAD+ in humans (Trammell et al., Nat Commun 2016), and longer supplementation trials in healthy middle-aged and older adults have confirmed both the elevation and reasonable tolerability (Martens et al., Nat Commun 2018).
Claim three — raising NAD+ improves health outcomes in humans. This is where it thins out. Animal work is consistently positive: better metabolic markers, better mitochondrial function, extended lifespan in some species. Human trials have generally been small, short, and focused on intermediate endpoints, and the results have been mixed rather than absent — some show a measurable functional change, others show the NAD+ level rise with little else moving (Yoshino et al., Science 2021).
The gap between claims two and three is the whole argument. Blood NAD+ is a convenient measurement, not necessarily the relevant one — what matters is NAD+ inside specific tissues and compartments, available to specific enzymes, and a rise in circulating levels does not guarantee any of that. It is entirely possible to move the marker without moving the biology.
Delivery routes
| Route | Notes |
|---|---|
| Oral NMN (nicotinamide mononucleotide) | Reliable NAD+ elevation; convenient; lower cost |
| Oral NR (nicotinamide riboside) | Similar to NMN; both well-evidenced for blood NAD+ rise |
| Subcutaneous NAD+ | Direct delivery; subjectively reported strong effects |
| IV NAD+ infusion | Highest acute exposure; intense subjective experience |
| Intranasal NAD+ | Convenient; emerging |
Note what that table does and does not say. Every route is described by how much NAD+ it delivers, because that is the endpoint measured; none by a clinical outcome, because those comparisons have not been made. Choosing a route is a choice about exposure, convenience and cost — not efficacy, which nobody can rank.
NMN versus NR
Both raise NAD+ and both enter the salvage pathway, differing in where they join it. The practical distinction is regulatory rather than biological: FDA action removed NMN from dietary supplement status, treating it as an investigational drug, which has made NR the more available option over the counter. Anyone claiming a decisive biological advantage for either is going beyond the human evidence.
IV NAD+, and the honest problem with it
IV infusions deliver a large dose over a two to four hour session, and many people report a strong short-term effect — mental clarity, energy, a sense of well-being. The subjective experience is real and consistently described.
The difficulty is interpreting it. An expensive, time-consuming, physically distinctive intervention delivered in a clinical setting is close to a maximally placebo-favourable design, and the acute effects reported have not been separated from expectation under controlled conditions. That is not a claim the effect is imaginary — it is a statement that the study which would settle it has not been done.
Who this is actually for
The useful framing is order of operations rather than yes or no.
- Adults over 40 who have already addressed sleep, training, nutrition and any hormone deficiency, and are looking at the next tier
- People recovering from significant illness
- Those running a comprehensive longevity protocol where this is one component among several
- People investigating persistent fatigue where the standard workup has come back unremarkable — with the caveat that this is a reason to look harder, not a reason to supplement instead of looking
It is not a substitute for correcting an actual deficiency, for sleep, for training, or for the metabolic basics — those have stronger evidence, larger effects and lower cost. The habits with the best evidence are the honest comparison set, and exercise-driven mitochondrial biogenesis reaches much of the same machinery for free.
The principle: NAD+ is plausible, popular and partially evidenced. It is a refined adjunct, not a foundation. For someone with the foundations genuinely handled and resources to spend on plausible-but-emerging tools, it has a place. For someone deciding between NAD+ and fixing their sleep, fix the sleep — the effect size is larger and the evidence is not in question.
What to expect if you try it
Set expectations in advance, because here the absence of a dramatic effect gets misread as a failed protocol rather than the likely outcome. Oral precursors raise blood NAD+ within weeks; whether you feel anything is separate, and many people do not. There is no established biomarker that tells you it is working — a blood NAD+ level tells you the precursor was absorbed, not that anything downstream changed. Long-term safety data at commonly used amounts shows no major signals but is still maturing. A sensible trial is a defined period, a defined thing you are watching for, and a willingness to stop if nothing changes. A physician review is the place to establish whether the foundations are genuinely handled first.
Bottom line
NAD+ is real infrastructure, it really does decline with age, and precursors really do raise it. The step that has not been demonstrated is that raising it changes health outcomes in humans — animal data is consistently supportive, human data is small, short and mixed, and blood levels may not reflect what is happening inside the tissues that matter. That makes NAD+ a reasonable next-tier addition for someone whose sleep, training, nutrition and hormones are already handled, and a poor first purchase for anyone whose are not. Judge it as a plausible bet on emerging evidence, which is what it is, rather than as an established intervention, which it is not yet.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
